Crushing the competition! Eli Lilly & Co's Mounjaro becomes the best-selling drug in India in October.

Research company Pharmarack stated on Friday that Eli Lilly's blockbuster obesity drug Mounjaro, with sales of 1 billion rupees (approximately $11.38 million), has become the best-selling drug in India in terms of sales in October. This type of heavyweight weight loss drug, which combines sugar control and delayed digestion effects, has seen a continuous rise in demand in this country with the largest population in the world. The company stated that Lilly launched Mounjaro in March, earlier than competitor Novo Nordisk A/S Sponsored ADR Class B company's Wegovy, which was launched in June. By the end of October, Mounjaro's cumulative revenue had reached 3.33 billion rupees. Pharmarack also pointed out that in the Indian market in October, sales of Mounjaro were 10 times that of Wegovy. Recently, Lilly released its third-quarter financial report, with sales of $17.6 billion, exceeding the average Wall Street expectation of $16.1 billion; non-GAAP earnings per share were $7.02, surpassing the expected $1.13. Furthermore, due to the better-than-expected revenue from heavyweight weight loss drugs and diabetes drugs in Q3, the company has raised its full-year performance guidance. This is a positive development for the pharmaceutical company, which is currently facing intense competition.